Key result
Baseline TGF-β1/endoglin ratio strongly correlates with aortic diameter growth in non-dilated bicuspid aortic valves.
Why the study?
The pathogenesis of bicuspid aortic valve-associated aortopathy is poorly understood and no prognostic biomarker is currently available.
Does the serum TGF-β1/endoglin (T/E) ratio correlate with aortic diameter growth rate in patients with bicuspid aortic valve?
Comparison
BAV patients versus tricuspid aortic valve patients and healthy subjects
Design
Observational study with gene expression, protein analysis, and serum biomarker assessment
Follow-up
Follow-up echocardiography in BAV non-dilated patients to assess aortic growth rate
Authors
Loading...
Elevated T/E ratio was associated with faster aortic growth in non-dilated BAV; leaves open its role as a prognostic biomarker pending validation.
Observational (n=150)
Does the serum TGF-β1/endoglin (T/E) ratio correlate with aortic diameter growth rate in patients with bicuspid aortic valve?
Effect estimate: r=0.66
p-value: p=<0.001
The serum TGF-β1/endoglin ratio may serve as a novel prognostic biomarker for predicting aortic dilation in patients with bicuspid aortic valve.
Forte et al. (2017) conducted an observational in Bicuspid aortopathy (n=150). Serum TGF-β1/ENG (T/E) ratio vs. Healthy subjects and tricuspid aortic valve patients was evaluated on Aortic diameter growth rate (r=0.66, p=<0.001). The baseline serum TGF-β1/endoglin ratio significantly correlated with aortic diameter growth rate in patients with non-dilated bicuspid aortic valves (r=0.66, P<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: